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BMS-284756 is 10-fold more active than ciprofloxacin against staphylococci (MIC 50 0.03 mg/L) 1 and has threefold greater drug exposure (3 ϫ AUC of ciprofloxacin using standard doses), 4 indicating that BMS-284756 may be of potential use for treatment of MRSA infection.
In this study, we compared the activity of BMS-284756 with those of levofloxacin and ciprofloxacin against 144 mecA ϩ and 124 mecA Ϫ staphylococcal strains. All strains were clinical isolates collected within the past 5 years. GISA (glycopeptide-intermediate susceptible S. aureus) strains were kindly provided by T. Walsh (Bristol, UK), and the BORSA (borderline oxacillin-resistant S. aureus) isolates were obtained from J. Swenson (CDC, Atlanta, GA, USA) and L. Jette (Labortoire de Sante Publique de Quebec, Canada). S. aureus was identified by a positive tube coagulase test. Coagulase-negative staphylococcal strains were speciated using the API-Staph system (bioMérieux, Hazelwood, MO, USA).
BMS-284756 was obtained from Toyama Chemical Co. Ltd, Toyama, Japan; ciprofloxacin from Bayer Corporation, West Haven, CT, USA; levofloxacin was extracted and purified from commercially available tablets and determined to be Ͼ95% pure by high-performance liquid chromatography; and oxacillin was purchased from Sigma Chemical Co., St Louis, MO, USA.
Genotypic determination of methicillin resistance was done by detection of the mecA gene, following the PCR procedure of Bignardi et al. 5 MICs were determined by an agar dilution method, using Mueller-Hinton agar (MHA), and, for oxacillin, MHA ϩ 2% NaCl. Bacterial inoculum size was c. 5 ϫ 10 4 cfu/spot, and plates were incubated at 35°C for 24 h. The MIC endpoint was read as the lowest drug concentration that prevented visible growth.
BMS-284756 was the most active quinolone against staphylococci. Based on MIC 90 or modal MIC values (Table) , BMS-284756 was more active than ciprofloxacin and levofloxacin, by four to eight times against mecA Ϫ staphylococcal strains, with an even greater differential (32-128 times) against BORSA strains.
Most notable was the enhanced potency of BMS-284756 against methicillin-resistant staphylococci. Compared with levofloxacin and ciprofloxacin, BMS-284756 was у16 times more active against MRSA. BMS-284756 was four-fold more active than levofloxacin, 32-fold more active than ciprofloxacin against mecA ϩ Staphylococcus epidermidis, and two-fold more active than levofloxacin and over eight times more active than ciprofloxacin against mecA ϩ Staphylococcus haemolyticus isolates. Similarly, BMS-284756 was four to eight times more potent than the comparator quinolones against other mecA ϩ species of coagulasenegative staphylococci, and eight-fold or more active than comparators against mecA ϩ GISA strains. Based on its AUC following a 400 mg oral dose, the tentative BMS-284756 susceptibility breakpoint for MRSA strains is р2 mg/L. 4 Ninety per cent of MRSA, 56% of GISA, 97% of oxacillin-resistant S. epidermidis, 89% of mecA ϩ S. haemolyticus and 100% of all mecA ϩ strains belonging to other coagulase-negative Staphylococcus spp. had BMS-284756 MICs of р2 mg/L.
These results indicate that BMS-284756 is more active than comparator quinolones against methicillin-resistant staphylococci. Given that these strains are often multidrug resistant, and that the few agents with activity against MRSA (such as vancomycin, linezolid and quinupristin/ dalfopristin) are bacteriostatic or poorly bactericidal, 6 BMS-284756 may provide a therapeutic alternative for infections caused by these pathogens. 
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